Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PBH
stocks logo

PBH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q4
FY2027Q1
286.93M
-1.17%
1.155
-5.33%
303.80M
+2.45%
1.398
+5.93%
257.64M
+3.25%
1.000
+5.26%
Estimates Revision
The market is revising Upward the revenue expectations for Prestige Consumer Healthcare Inc. (PBH) for FY2026, with the revenue forecasts being adjusted by 0.11% over the past three months. During the same period, the stock price has changed by -7.67%.
Revenue Estimates for FY2026
Revise Upward
up Image
+0.11%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
up Image
+0.48%
In Past 3 Month
Stock Price
Go Down
down Image
-7.67%
In Past 3 Month
Wall Street analysts forecast PBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBH is 77.75 USD with a low forecast of 71.00 USD and a high forecast of 88.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast PBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBH is 77.75 USD with a low forecast of 71.00 USD and a high forecast of 88.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 60.060
sliders
Low
71.00
Averages
77.75
High
88.00
Current: 60.060
sliders
Low
71.00
Averages
77.75
High
88.00
Canaccord
Susan Anderson
Buy
downgrade
$100 -> $88
2025-11-07
Reason
Canaccord
Susan Anderson
Price Target
$100 -> $88
2025-11-07
downgrade
Buy
Reason
Canaccord analyst Susan Anderson lowered the firm's price target on Prestige Consumer to $88 from $100 and keeps a Buy rating on the shares. The firm said they posted solid results and management noted that sales and earnings exceeded expectations due to Clear Eyes supply timing and the timing of certain retailer orders, though this will come out of 3Q now.
Jefferies
Hold
downgrade
$75 -> $71
2025-10-27
Reason
Jefferies
Price Target
$75 -> $71
2025-10-27
downgrade
Hold
Reason
Jefferies lowered the firm's price target on Prestige Consumer to $71 from $75 and keeps a Hold rating on the shares. Macro headwinds continue to be felt more acutely in consumer health than other pockets of staples, says the analyst, who lowered targets and estimates across the firm's consumer health coverage into Q3 earnings reports from the group.
Oppenheimer
Rupesh Parikh
Outperform
to
Outperform
downgrade
$82 -> $72
2025-10-21
Reason
Oppenheimer
Rupesh Parikh
Price Target
$82 -> $72
2025-10-21
downgrade
Outperform
to
Outperform
Reason
Oppenheimer analyst Rupesh Parikh lowered the firm's price target on Prestige Consumer to $72 from $82 and keeps an Outperform rating on the shares. Ahead of upcoming consumer staples reports, the firm has updated its thinking on the group and a few names. Consistent with Oppenheimer's views for the past several quarters, the firm continues to see a difficult fundamental backdrop for the broader CPG space driven by limited pricing power for a number of players, GLP-1 risks for food names, a still significant focus from leading retailers on private label, tariff risks, and shifting consumer tastes/preferences.
Sidoti
Anthony Lebiedzinski
Neutral -> Buy
upgrade
$80
2025-09-24
Reason
Sidoti
Anthony Lebiedzinski
Price Target
$80
2025-09-24
upgrade
Neutral -> Buy
Reason
Sidoti analyst Anthony Lebiedzinski upgraded Prestige Consumer to Buy from Neutral with an $80 price target.
Canaccord
Buy
downgrade
$105 -> $100
2025-08-08
Reason
Canaccord
Price Target
$105 -> $100
2025-08-08
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Prestige Consumer to $100 from $105 and keeps a Buy rating on the shares. The firm noted thier Q1 results missed expectations despite management noting strong international segment growth year-over-year, improvement in gross margin, and solid FCF. However, this was offset by Clear Eyes supply constraints which resulted in lower-than-expected shipments.
RBC Capital
Ryland Conrad
Hold
Maintains
$96 → $97
2025-03-21
Reason
RBC Capital
Ryland Conrad
Price Target
$96 → $97
2025-03-21
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Prestige Consumer Healthcare Inc (PBH.N) is 12.84, compared to its 5-year average forward P/E of 14.36. For a more detailed relative valuation and DCF analysis to assess Prestige Consumer Healthcare Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
14.36
Current PE
12.84
Overvalued PE
16.05
Undervalued PE
12.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
11.59
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
12.47
Undervalued EV/EBITDA
10.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.76
Current PS
0.00
Overvalued PS
3.18
Undervalued PS
2.35
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 622.44% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PBH News & Events

Events Timeline

(ET)
2025-11-06
06:26:06
Prestige Consumer updates FY26 adjusted EPS forecast to a range of $4.54-$4.58, revised from $4.50-$4.58.
select
2025-11-06
06:23:49
Prestige Consumer announces Q2 adjusted EPS of $1.07, surpassing consensus estimate of 97 cents.
select
2025-06-17 (ET)
2025-06-17
17:42:58
Medtech recalls Little Remedies Honey Cough Syrup due to contamination
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-06NASDAQ.COM
Prestige Consumer Healthcare Inc. Reports Decline in Q2 Profit, Surpassing Expectations

  • Earnings Report: Prestige Consumer Healthcare Inc. reported a second-quarter profit of $42.21 million, down from $54.37 million last year, but exceeded analysts' expectations of $0.97 per share with adjusted earnings of $1.07 per share.

  • Revenue Decline: The company's revenue decreased by 3.4% to $274.11 million compared to $283.78 million in the same quarter last year.

  • Earnings Per Share Comparison: The earnings per share (EPS) for the quarter was $0.86, compared to $1.09 in the previous year.

  • Future Guidance: Prestige Consumer Healthcare provided full-year EPS guidance of $4.54 - $4.58 and revenue guidance of $1,100 - $1,115 million.

[object Object]
Preview
6.0
11-05Benzinga
RBC Capital Reaffirms Outperform Rating for Premium Brands Holdings, Increases Price Target to C$118

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.

[object Object]
Preview
5.0
10-24SeekingAlpha
Ariel Focus Fund acquires AJG, PBH, and FI while divesting from ZIMV, CLB, and BIO.

  • Fund Performance: Ariel Focus Fund achieved a growth of 20.76% in Q3 2025, significantly outperforming the Russell 1000 Value Index (5.33%) and the S&P 500 Index (8.12%).

  • New Investments: The fund initiated new positions in Prestige Consumer Healthcare, Arthur J. Gallagher, and Fiserv during the third quarter.

  • Exits from Investments: In Q3 2025, the fund exited its positions in Zimvie, Core Laboratories, and Bio-Rad Laboratories.

  • Core Laboratories Outlook: Core Laboratories projects Q4 2025 revenue between $132M and $136M, driven by international demand.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Prestige Consumer Healthcare Inc (PBH) stock price today?

The current price of PBH is 60.06 USD — it has decreased -0.36 % in the last trading day.

arrow icon

What is Prestige Consumer Healthcare Inc (PBH)'s business?

Prestige Consumer Healthcare Inc. is a consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.

arrow icon

What is the price predicton of PBH Stock?

Wall Street analysts forecast PBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBH is 77.75 USD with a low forecast of 71.00 USD and a high forecast of 88.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Prestige Consumer Healthcare Inc (PBH)'s revenue for the last quarter?

Prestige Consumer Healthcare Inc revenue for the last quarter amounts to 274.11M USD, decreased -3.41 % YoY.

arrow icon

What is Prestige Consumer Healthcare Inc (PBH)'s earnings per share (EPS) for the last quarter?

Prestige Consumer Healthcare Inc. EPS for the last quarter amounts to 0.86 USD, decreased -21.10 % YoY.

arrow icon

What changes have occurred in the market's expectations for Prestige Consumer Healthcare Inc (PBH)'s fundamentals?

The market is revising Upward the revenue expectations for Prestige Consumer Healthcare Inc. (PBH) for FY2026, with the revenue forecasts being adjusted by 0.11% over the past three months. During the same period, the stock price has changed by -7.67%.
arrow icon

How many employees does Prestige Consumer Healthcare Inc (PBH). have?

Prestige Consumer Healthcare Inc (PBH) has 600 emplpoyees as of December 05 2025.

arrow icon

What is Prestige Consumer Healthcare Inc (PBH) market cap?

Today PBH has the market capitalization of 2.89B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free